ITM Signs Supply Deal to Provide Radiopharm with Lutetium-177 for Cancer Therapies

• Radiopharm Theranostics will use ITM’s non-carrier-added Lutetium-177 (n.c.a. 177Lu) in its clinical and potential commercial programmes.

• The supply agreement covers advanced assets in Radiopharm’s pipeline, including trials targeting PD-L1, HER2, and B7-H3 in solid tumours.

ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company, has signed a supply agreement with Radiopharm Theranostics to provide its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu). The agreement will support Radiopharm’s ongoing and future development of targeted radiopharmaceutical therapies for solid tumours.

The agreement includes the use of ITM’s n.c.a. 177Lu in several key Radiopharm programmes: RAD 204 (PD-L1-targeting nanobody, Phase 1), RAD 202 (HER2-targeting nanobody, Phase 1), and RV01 (B7-H3-targeting monoclonal antibody, preclinical). These therapies are designed to deliver the radioisotope directly to cancer cells, using its beta radiation to destroy malignant tissue in a precise and localised manner.

“Lutetium-177 is required for three of our more advanced assets and this supply agreement with a radiopharmaceutical leader like ITM is another important step to ensure quality, reliability, and redundancy in our clinical development plans,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.

ITM’s n.c.a. 177Lu is a highly pure beta-emitting isotope approved for use in both the U.S. and the EU (marketed as EndolucinBeta). The company holds a Drug Master File with the FDA and has supplied the isotope for a range of clinical and commercial cancer therapies.

“As the leading global manufacturer of non-carrier-added Lutetium-177, we are just as committed to supplying our global partners with high-quality medical radioisotopes as we are to supplying our own pipeline,” said Andrew Cavey, CEO of ITM.